Results 1 to 10 of about 780 (156)

Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19).
Jing Zhang, Fang Wang, Ying Xie, Qianyu Li, Zhenzhen Zhu, Yuan Dong   +5 more
doaj   +5 more sources

Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study [PDF]

Advanced Science
Azvudine is recommended as a priority treatment for patients with Coronavirus Disease 2019 (COVID‐19) during Omicron wave in China, but its efficacy and safety in elderly patients is unknown.
Ranran Sun, Haiyu Wang, Junyi Sun, Mengzhao Yang, Shixi Zhang, Xinjun Hu, Bo Yu, Zhan Song, Na Han, Hong Luo, Ming Cheng, Guangming Li, Guotao Li, Yiqiang Yuan, Lili Liang, Yanyang Zhang, Donghua Zhang, Silin Li, Quancheng Kan, Hongxia Liang, Zhigang Ren   +20 more
doaj   +3 more sources

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19 [PDF]

Scientific Reports
Cancer significantly contributes to the unfavorable prognosis of coronavirus disease 2019 (COVID-19) patients. The efficacy and safety of azvudine and nirmatrelvir/ritonavir (Paxlovid) in cancer patients with COVID-19 remain uncertain.
Bohan Jia, Junyi Sun, Di Zhu, Ling Wang, Xiaobo Hu, Haiyu Wang, Guowu Qian, Donghua Zhang, Silin Li, Hong Luo, Shixi Zhang, Guotao Li, Guangming Li, Hongxia Liang, Zujiang Yu, Zhigang Ren   +15 more
doaj   +4 more sources

Impact of early and delayed azvudine administration on COVID-19 mortality: a retrospective study [PDF]

Scientific Reports
Azvudine is recommended for patients with coronavirus disease 19 (COVID-19); however, its optimum therapeutic time window and its impact on mortality of patients are unclear.
Luo Wang, Yaqi Wang, Yan Xu, Junping Fan, Siqi Pan, Huaiya Xie, Ting Zhang, Ruxuan Chen, Xiaoyan Liu, Chuan Shi, Qing Zhou, Yuequan Shi, Chongsheng Cheng, Lu Dai, Haoran Zhang, Aohua Wu, Xueqi Liu, Hong Zhang, Jinglan Wang, Bin Du, Jihai Liu, Huadong Zhu, Xiaojun Ma, Jing Huang, Xinlun Tian, Mengzhao Wang, Shuyang Zhang   +26 more
doaj   +3 more sources

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials [PDF]

Frontiers in Pharmacology, 2023
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
doaj   +3 more sources

Real-world data of Azvudine-induced hepatotoxicity among hospitalized COVID-19 patients in China: a retrospective case-control study [PDF]

Frontiers in Pharmacology
BackgroundThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global health crisis. Although several antiviral drugs have been used to mitigate the severity and mortality of COVID-19, the safety profile remained a critical concern. Azvudine,
Yuanguo Xiong, Hao Xin, Cai Shi, Xianxi Guo, Ying Chen, Caifei Huang, Fuwang Ma, Ge Yang, Jian Yang   +8 more
doaj   +2 more sources

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study. [PDF]

Front Pharmacol
ObjectiveTo explore the effectiveness and safety of azvudine and nirmatrelvir-ritonavir in a real-world setting.MethodsThis retrospective cohort study included adult patients with confirmed COVID-19 who received azvudine or nirmatrelvir-ritonavir ...
Chen J, Liu Z, Liu R, Su C, Yang Y, Wang Z.   +5 more
europepmc   +3 more sources

Real-world effectiveness and safety of oral azvudine versus Paxlovid in patients with COVID-19 and pre-existing hypertension: a multicentre, retrospective, cohort study in Henan Province, China [PDF]

BMJ Open
Objectives Azvudine and Paxlovid are the primary antiviral agents for the management of COVID-19. However, there is currently insufficient evidence regarding the effectiveness and safety of these drugs in treating COVID-19 patients with pre-existing ...
Ling Wang, Zhigang Ren, Xiaoli Jin, Hong Luo, Donghua Zhang, Ming Cheng, Fuwei Wang, Bohan Jia, Guotao Li, Mengzhao Yang, Guangming Li, Shixi Zhang, Guowu Qian, Silin Li, Hongxia Liang   +14 more
doaj   +2 more sources

Evaluating the effectiveness and safety of Azvudine for hospitalised patients with COVID-19 and hypertension: a multicenter retrospective cohort study [PDF]

Scientific Reports
Hypertension is widely acknowledged as a major risk factor for disease severity and death in patients with coronavirus disease 2019 (COVID-19). Azvudine is recommended for COVID-19 patients in China.
Yu Chen, Huan Li, Yichen Ma, Ling Wang, Guowu Qian, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yun Zheng, Qin Bai, Haiyu Wang, Zhigang Ren   +14 more
doaj   +2 more sources

Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study [PDF]

Signal Transduction and Targeted Therapy
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized
Haiyu Wang, Guangying Cui, Ming Cheng, Tuerganaili Aji, Guotao Li, Xinjun Hu, Guangming Li, Shixi Zhang, Yanyang Zhang, Linqi Diao, Pan Li, Ling Wang, Yiqiang Yuan, Guowu Qian, Ruiqing Zhang, Xiaoli Jin, Juan Wang, Hong Luo, Donghua Zhang, Mingming Wang, Silin Li, Zhan Song, Mengzhao Yang, Guanyue Su, Ranran Sun, Junbiao Chang, Zujiang Yu, Zhigang Ren   +27 more
doaj   +2 more sources